# A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS

> **NCT03319732** · PHASE3 · COMPLETED · sponsor: **RVL Pharmaceuticals, Inc.** · enrollment: 323 (actual)

## Conditions studied

- Multiple Sclerosis
- Spasticity, Muscle

## Interventions

- **DRUG:** Arbaclofen

## Key facts

- **NCT ID:** NCT03319732
- **Lead sponsor:** RVL Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-03
- **Primary completion:** 2020-01-27
- **Final completion:** 2020-06-11
- **Target enrollment:** 323 (ACTUAL)
- **Last updated:** 2022-08-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03319732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03319732, "A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03319732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*